133 related articles for article (PubMed ID: 23090080)
1. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
Joseph RW; Eckel-Passow JE; Sharma R; Liu P; Parker A; Jakob J; Buchbinder E; Bassett RL; Davies MA; Hwu P; Atkins MB; Sullivan RJ
J Immunother; 2012; 35(9):711-5. PubMed ID: 23090080
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C
J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567
[TBL] [Abstract][Full Text] [Related]
4. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
5. High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.
Buzaid AC; Schmerling RA; Vieira Guedes RA; de Freitas D; William WN
Melanoma Res; 2011 Aug; 21(4):370-5. PubMed ID: 21558968
[TBL] [Abstract][Full Text] [Related]
6. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
7. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
Davar D; Ding F; Saul M; Sander C; Tarhini AA; Kirkwood JM; Tawbi HA
J Immunother Cancer; 2017 Sep; 5(1):74. PubMed ID: 28923120
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.
Jiang BS; Beasley GM; Speicher PJ; Mosca PJ; Morse MA; Hanks B; Salama A; Tyler DS
Ann Surg Oncol; 2014 Aug; 21(8):2525-31. PubMed ID: 24700302
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Buchbinder EI; Gunturi A; Perritt J; Dutcher J; Aung S; Kaufman HL; Ernstoff MS; Miletello GP; Curti BD; Daniels GA; Patel SP; Kirkwood JM; Hallmeyer S; Clark JI; Gonzalez R; Richart JM; Lutzky J; Morse MA; Sullivan RJ; McDermott DF
J Immunother Cancer; 2016; 4():52. PubMed ID: 27660706
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P
J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900
[TBL] [Abstract][Full Text] [Related]
16. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
Gebhardt C; Sevko A; Jiang H; Lichtenberger R; Reith M; Tarnanidis K; Holland-Letz T; Umansky L; Beckhove P; Sucker A; Schadendorf D; Utikal J; Umansky V
Clin Cancer Res; 2015 Dec; 21(24):5453-9. PubMed ID: 26289067
[TBL] [Abstract][Full Text] [Related]
17. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Ferrucci PF; Gandini S; Battaglia A; Alfieri S; Di Giacomo AM; Giannarelli D; Cappellini GC; De Galitiis F; Marchetti P; Amato G; Lazzeri A; Pala L; Cocorocchio E; Martinoli C
Br J Cancer; 2015 Jun; 112(12):1904-10. PubMed ID: 26010413
[TBL] [Abstract][Full Text] [Related]
18. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
19. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
Wilgenhof S; Du Four S; Vandenbroucke F; Everaert H; Salmon I; Liénard D; Marmol VD; Neyns B
J Immunother; 2013 Apr; 36(3):215-22. PubMed ID: 23502769
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
